Zombie Biotech Bite Lilly’s Flab Fight Flops
This week’s ‘The Readout LOUD’ brings us the sad, slow death of a zombie biotech, proving you can’t just stitch dead companies back to life. Meanwhile, Lilly’s obesity drug results are as underwhelming as a flat soda—described simply as ‘disappointing obesity readout.’ If we were looking for a plot twist, we’d better sit down: pharma’s horror story continues with a whimper rather than a bang.
Share the Story
When zombie biotechs stumble and Lilly’s obesity hopes deflate, it’s official: pharma’s more horror story than thriller right now.
Nothing like a biotech graveyard plus disappointment in obesity trials to remind us life and science both love an ironic twist.
If your biotech’s a zombie and your obesity study flops, congrats—you’re the pharmaceutical equivalent of a microwave dinner no one really wanted.
Source: Statnews | Published: 8/7/2025 | Author: Adam Feuerstein, Elaine Chen, and Allison DeAngelis
More Articles in Health
Digital Nomad Trapped in Lisbon FOMO, Ends Up BFF Ghosted
Grandfather Gifts $1,500 with Guest Star Role for Financial Advisor
TCL and Hisense Finally Throw Shade at Sony, LG, Samsung’s Premium TV Party
Kennedy’s Protein-Heavy Food Pyramid: Eat More Meat, But Not Saturated Fat, Or Something
Parents Swap 'Because I Said So' For 'Oops, You Bought Too Much Junk'
America Celebrates Lower Gun Deaths While Puffing More Vape Clouds
Trump's Vaccine Makeover: Fewer Shots, More Trust, Same Measles Risks
Woman’s Epic Fight: Type 1 Diabetes vs. Ancient Mexican Ruins Timer
